Press Releases

LEXINGTON, Mass. , April 12, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc . (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today presented
Read More
Johan van Hylckama Vlieg, Ph.D., Named Chief Scientific Officer and Clare Fisher Appointed Chief Business Officer LEXINGTON, Mass. , April 08, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc . (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to
Read More
LEXINGTON, Mass. , March 08, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences , (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that a
Read More
LEXINGTON, Mass. , March 04, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced the
Read More
LEXINGTON, Mass. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced the
Read More
Print Page
Email Alerts
RSS
Investor Contact
Search